We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Magneto-plasmonic Nanoparticle Platform for Capture, Separation and Enumeration of Rare Cells

Video   May 27, 2014

 

Abstract

Detection of disseminated tumor cells or tumor biomarkers in human fluids such as blood, urine, and saliva can provide an accessible tool for cancer detection and therapy monitoring. In particular, accurate quantitation of cancer cells in the bloodstream can help to determine prognosis and monitor the effectiveness of cancer therapy. However, the challenge of detecting circulating tumor cells (CTCs) is their rare occurrence, estimated as one to few CTCs among millions of leukocytes and billions of erythrocytes. Here we address this challenging problem by developing nanoparticle probes with multiple functionalities.

 
 
 
 

Recommended Videos

Cancer Treatment Using Nanoparticles – Is It Possible?

Video

Nanoparticles are capable of carrying chemotherapy to areas of the body afflicted by cancer. However, what if these nanoparticles were specifically targeted to treat only cancer cells and not healthy cells?

WATCH NOW

Launch of the Malaria Vaccine in Ghana

Video

The world’s first malaria vaccine in childhood vaccination is being rolled out in 2019 in selected areas of Ghana, Malawi and Kenya, through a pilot programme supported by the World Health Organization.

WATCH NOW

CaptSure™ DIY ELISA - Fastest ELISA development without need for plate coating

Video

CaptSure DIY ELISA is the latest cutting-edge ELISA kit with a built-in system for antibody labeling, enabling the rapid and easy development of in-house ELISAs using any antibody pair while eliminating the need to perform plate coating procedures.

WATCH NOW

 

Like what you just watched? You can find similar content on the communities below.

Applied Sciences Cancer Research Drug Discovery Proteomics & Metabolomics Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE